Earth Science Tech Announces New Wholly Owned Subs

Hollywood, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is pleased to announce its new wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals. 

Cannabis Therapeutics, Inc. will begin by inventing & launching Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid (phytocannabinoids and synthetic cannabinoids) research and development for a broad line of cannabis cannabinoid-based therapeutic pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company has appointed Dr. Michel Aube as the CEO and Nickolas Tabraue as the President of Cannabis Therapeutics, Inc. CEO of Cannabis Therapeutics, Inc., Dr. Michel Aube, stated, “I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists. ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide.” Cannabis Therapeutics looks to discover and bring to market innovative solutions through its R&D, joint ventures and strategic partnerships by setting the highest quality standard in the cannabis-industrial hemp industry. Cannabis Therapeutics board of directors and upcoming new scientific advisory board intends to broaden the current operations of the Cannabis Therapeutics to include a variety of other products, solutions, laboratories and expertise, natural molecules, generic drugs, new compounds and new synthetic molecules, extraction and refinement of biomaterials, technologies and IP. Cannabis Therapeutics, Inc will look to distinguish itself from many competing cannabinoid-focused biotechnology companies with its competent capital apportionment. While larger biotechnology companies spend millions and millions on clinical trials, Cannabis Therapeutics will look to very efficient with capital allocation in inventing & launching its Two (2) New Cannabinoid-based Pharmaceutical drugs which will be tested to treat roughly five (5) diseases with the help of its strategic partnerships. Cannabis Therapeutics goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain , Chronic Pain , PTSD , Breast Cancer , Brain Cancer , Anxiety , Depression , Glaucoma , Crohn’s disease , Fatty Liver Diseases , Diabetes , Parkinson's Disease , Alzheimer's Disease , Attention Deficit Hyperactivity Disorder (ADHD)  and Drug Addictions  among other things.

ETST will be announcing its new joint venture partner in Canada by February 15, 2017, that will give Cannabis Therapeutics access to state of the art laboratory facilities to develop these World Class Cannabis Cannabinoid-based Pharmaceutical Drugs & CBD (Cannabidiol) health and wellness Nutraceuticals products to help alleviate certain conditions and disorders for people worldwide.

ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer , immune cell function , and human brain cells  by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases.

ETST’s CBD-Nutraceutical (functional food) products are designed to alleviate common symptoms and prevent illnesses. The products can improve the overall wellbeing of an individual such as; brain function, diabetes, inflammation, and immune cell functions.

ETST is targeting the above-mentioned conditions as Cannabinoids continuously proves to work against each of them at cellular level. Starting with our recent research in deciphering the molecular action of CBD, ETST has been carefully choosing natural molecules that compliment or support CBD as well as developing formulations that blend CBD with whole plant extracts and pure natural molecules that are natural antioxidants and/or flavonoids. Together these ingredients work synergistically with CBD to improve detoxification of the brain and the liver, while improving immune function and diabetes. ETST’s advanced products will deliver the Cannabinoid and/or CBD molecule at maximum efficiency and will be available to everyone to continue improving lives worldwide.

CEO of ETST and Cannabis Therapeutics, Dr. Michel Aubé states, “Our Cannabinoid-Pharmaceutical Drugs will be designed to help treat a variety of things including, but not limited to anxiety, depression, triple negative breast cancer, and fatty liver disease. Together, these diseases and disorders represent a massive market. Mental disorders are increasing worldwide. I look forward into soon discussing further details in regards to the R&D of our Cannabis Cannabinoid-Pharmaceutical Drug Pipeline. According to the World Health Organization, between 1990 and 2013 the number of people suffering from depression and/or anxiety increased by nearly 50%. Depression and anxiety disorders cost the global economy US$1 trillion each year. The substantial burden of anxiety-related disorders and the limitations of existing treatments give urgency to developing novel pharmaceutical treatments.”

CEO of ETST and Cannabis Therapeutics, Dr. Michel Aubé continues, “With my team of scientific researchers and laboratory resources in Canada, ETST and Cannabis Therapeutics now has the scientific expertise and the clinical support needed to develop these Cannabis Cannabinoid-based products for the health benefit of people worldwide. Having several additional unique, advanced CBD nutraceutical products on the market will grant ETST and Cannabis Therapeutics a competitive advantage, thus consequently solidifying its leadership position in that market. Our two planned Cannabinoid-based Pharmaceutical drugs will allow us to enter a new industry, making us one of the very few companies in this arena.

It has been shown both in vitro and in vivo that CBD can improve the efficiency of existing breast cancer chemotherapy either in an additive or synergetic manner. We already know that CBD modulates Id-1 gene expression, which is a partial explanation of the mechanism by which CBD acts on breast cancer. We will take advantage of this interaction between CBD and Id-1 expression to develop a drug against triple negative breast cancer (TNBC). There is currently no appropriate treatment for this disease. Many clinical trials with TNBC patients are comparing the effectiveness of various older and newer chemotherapy medications, used in different combinations. It will be very interesting to test the potential of CBD to improve old medicines.”

Hepatic (liver) endocannabinoid levels are similar to those in the brain and they are important in the regulation of hepatic hemodynamics, fibrogenesis, as well as lipid metabolism, and in the dysregulation of these functions in liver pathological states. CBD has been shown in vivo to be efficient in treating non-alcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disease throughout the world. Several studies have demonstrated that oxidative stress is a major trigger of the progression of NAFLD to steato-hepatitis (non-alcoholic steato-hepatitis: NASH). NASH leads to exacerbation of inflammatory response and to liver cell dysfunction. A report, published by Allied Market Research, forecasts that the non-alcoholic steato-hepatitis market is expected to garner $1.6 billion by 2020 in North America alone. The high prevalence of Type II diabetes and obesity, which lead to NASH and NAFLD, will sustain that market’s growth. Type II diabetes shares many aspects of NAFLD, and other inflammatory processes in the adipose tissue and liver. Most non-alcoholic fatty liver disease patients are obese and at high risk of developing Type II diabetes. The number of patients living with diabetes worldwide is nearly 400 million and is expected to be more than 500 million by 2030.

Below Earth Science Tech has listed the FIELD OF THE INVENTION, BRIEF SUMMARY OF THE INVENTION and the BACKGROUND OF THE INVENTION for Earth Science Tech’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil.

Earth Science Tech International Application (PCT) on its Cannabis Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotectant.

FIELD OF THE INVENTION: The present invention relates to compositions for treating cancer, modulating the immune system, and providing neuroprotection against reactive oxygen species and lipid peroxidation using naturally occurring compounds. More particularly, the invention relates to the use of compositions containing compounds from hemp oil in the treatment of cancer, the modulation of the immune system, and the neuroprotection against reactive oxygen species and lipid peroxidation…. [Quote from the PCT Application]

BRIEF SUMMARY OF THE INVENTION: One object of the present invention is to provide a pharmaceutical composition for use in the treatment of cancer that includes Cannabidiol (CBD) and one or more of the following compounds.... Another object of the present invention is to provide a pharmaceutical composition for use in the treatment of cancer that includes hemp oil. The hemp oil is enriched with one or more of the following compounds…. Another object of the present invention is to provide a method of treating cancer (e.g., breast cancer). The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes Cannabidiol (CBD) and one or more of the following compounds…. Another object of the present invention is to provide a method of treating cancer (e.g., breast cancer). The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes hemp oil. The hemp oil is enriched with one or more of the following compounds…. [Quote from the PCT Application]

Another object of the present invention is to provide a method for activating the immune system. The method includes the stimulation of macrophages and the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method of modulating the immune system. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method for protecting human brain cells from reactive oxygen species and/or lipid peroxidation. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method that prevents the death of human brain cells. The method includes the administration of the pharmaceutical compositions. Another object of the present invention is to provide a method that provides neuroprotection against reactive oxygen species and lipid peroxidation. The present invention utilizes hemp oil as a source of CBD and other components as a composition useful in treating or preventing cancer…. [Quote from the PCT Application]

The pharmaceutical compositions may be used either alone or in combination with other treatments of cancer. These other treatments will depend on the type of cancer and can include but are not limited to surgery, chemotherapy, radiation therapy, immune therapy and laser photothermal therapy. These other treatments can be before, after or concurrent with the use of the pharmaceutical compositions of the present invention. Pharmaceutical compositions may take the form of any acceptable pharmaceutical formulation. Pharmaceutical compositions can be formulated in a variety of different forms, such as liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form can depend on the intended mode of administration and therapeutic application. The pharmaceutical compositions include those suitable for parenteral (including intravenous, subcutaneous, intradermal, intramuscular, and intraarticular), topical (including dermal, transdermal, transmucosal, buccal, sublingual, and intraocular), and rectal administration, although the most suitable route may depend upon, for example, the condition and disorder of the recipient. Compositions for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents…. [Quote from the PCT Application]

The pharmaceutical compositions and methods of the present invention may be administered concurrently or sequentially with one or more other treatment methods. These methods include but are not limited to chemotherapy, radiation therapy, immune therapy, laser photothermal therapy and surgery…. [Quote from the PCT Application]

As used herein, the phrases "treating cancer" and "treatment of cancer" mean to inhibit the replication of cancer cells, inhibit the spread of cancer, decrease tumor size, lessen or reduce the number of cancerous cells in the body, or ameliorate or alleviate the symptoms of the disease caused by the cancer. The treatment is considered therapeutic if there is a decrease in mortality and/or morbidity, or a decrease in disease burden manifest by reduced numbers of malignant cells in the body…. [Quote from the PCT Application]

A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the protein to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects…. [Quote from the PCT Application]

BACKGROUND OF THE INVENTION: Cannabidiol (“CBD”) is one of at least 85 active cannabinoids identified in hemp. It is a major phytocannabinoid, accounting for up to 40% of the plant's extract. CBD is considered to have a wider scope of therapeutic applications than tetrahydrocannabinol (“THC”). An orally-administered liquid containing CBD has recently been used to treat dravet syndrome, a rare type of epilepsy. CBD's strong anti-oxidant properties are believed to have neuroprotective and anti-ischemic effects. CBD is also believed to minimize or counteract some of the pyschotomimetic effects of THC. Due to the natural source of CBD, study of it has been limited until relatively recently and its medical benefits and effects have not been adequately studied.

U.S. Patent No. 6,630,507 titled "Cannabinoids as Antioxidants and Neuroprotectants," owned by the U.S. Department Of Health And Human Services, postulates that CBD may be an effective antiepileptic, may lower intraocular pressure in the treatment of glaucoma, demonstrates neuro-protective properties, attenuates glutamate toxicity, protects against cellular damage, protects the brain from ischemic damage, and exhibits superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases. The patent states “Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosus, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down's syndrome, Crohn's disease, autoimmune diseases (e.g., rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. The embodiments described in U.S. Patent No. 6,630,507 are believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. In particular embodiments of U.S. Patent No. 6,630,507, the pharmaceutical composition of the present invention is used for preventing, arresting, or treating neurological damage in Parkinson's disease, Alzheimer's disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock)…. [Quote from the PCT Application]

ETST is focused on the science, research and studies of its High-Grade Hemp CBD Oil as a health and wellness, nutraceutical and dietary supplement. Feel free to view some of our Scientific Research and Data  on Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) at http://earthsciencetech.com/scientific-research/. Cannabidiol (CBD) is a naturally occurring constituent of industrial hemp oil. Some of ETST accomplishments and reports on its High-Grade CBD Hemp Oil include:

• Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol). ( view here )
• Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes  Using ETST High Grade Hemp CBD (Cannabidiol).( view here )
• Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol)  Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection. ( view here )
• Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes.  ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD). ( view here )
• DV Biologics Reports:  Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant. ( view here )
• DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro. ( view here )
• Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function. ( view here ) 
• Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD(Cannabidiol) Rich Hemp Oil Because of Its Findings with the University of Central Oklahoma and the Effects of CBD on Immune Cells. ( view here ) 
• Earth Science Tech Announces Positive Preliminary Test Results  on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. ( view here )
• ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces  in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells. ( view here )

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

About Earth Science Tech:  ( www.earthsciencetech.com ) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Earth Science Tech, Inc. (305)-615-2118 Nickolas S. Tabraue, P/D/COO Source: Earth Science